Translational research in melanoma.
Current treatment of malignant melanoma exemplifies not only the need for translational research but also many of the challenges of moving from bench to bedside. Melanoma remains unique among solid tumors in that its treatment primarily is surgical. Radiation is of limited benefit, and chemotherapy has been disappointing in both the adjuvant and metastatic settings. This leaves clinicians with few options for reducing the chance of recurrence after surgery and for treating unresectable disease. With this in mind, there has been a fervent attempt to identify novel approaches to melanoma therapy and translate them into clinical use.
Tsai
Susan
S
University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Sabel
Michael S
MS
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D015703:Antigens, CD / Q000187:drug effects; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D003713:Dendritic Cells; D019317:Evidence-Based Medicine; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D016219:Immunotherapy, Adoptive / Q000379:methods; D008545:Melanoma / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D015398:Signal Transduction; D022223:Vaccines, Subunit / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D016588:Anticarcinogenic Agents; D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines; D022223:Vaccines, Subunit